Physician profile
Robert Yordan
NPI 1912001108
$1,433.69
in general payments reported to CMS, 2019-2025
20 companies · $128 in 2025
The $128 reported for 2025 was less than what a typical Obstetrics & Gynecology provider received nationally (typical 2025 total: $158).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $206 · 2020: $105 · 2021: $165 · 2022: $351 · 2023: $270 · 2024: $208 · 2025: $128.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $606.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $606.06 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $359.34 | 2020-2024 | Liletta |
| Astellas Pharma US INC | $246.46 | 2023-2025 | Veozah, Myrbetriq |
| Coopersurgical, INC. | $101.73 | 2019-2024 | Paragard T 380a |
| Exeltis, USA INC. | $101.72 | 2022-2024 | Slynd |
| Sumitomo Pharma America, INC. | $69.90 | 2023-2024 | Myfembree |
| Biohaven Pharmaceutical Holding Company LTD. | $61.88 | 2022 | |
| Allergan, INC. | $59.61 | 2019-2020 | |
| Pfizer INC. | $56.90 | 2019-2022 | |
| Therapeuticsmd, INC. | $55.93 | 2020-2021 | |
| Bayer Healthcare Pharmaceuticals INC. | $51.58 | 2023-2025 | |
| Evofem Biosciences, INC. | $45.07 | 2021 | |
| Millicent US INC | $38.41 | 2019-2025 | Femring, Intrarosa |
| Agile Therapeutics, INC. | $38.37 | 2022-2023 | Twirla |
| Avion Pharmaceuticals | $29.36 | 2019-2020 | |
| Lupin INC. | $27.27 | 2019-2020 |
Show all 20 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pacira Pharmaceuticals Incorporated | $23.20 | 2024 | Exparel |
| Urovant Sciences INC | $20.22 | 2022 | |
| Hologic Sales and Service, LLC | $17.40 | 2019 | |
| Amag Pharmaceuticals, INC. | $15.57 | 2019 | |
| Merck Sharp & Dohme LLC | $13.77 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Robert Yordan listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.